{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Corticosteroids&page=3", "query": { "intervention": "High Dose Corticosteroids", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 142, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Corticosteroids&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Corticosteroids&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T06:17:02.700Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004500", "title": "Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meconium Aspiration" ], "interventions": [ { "name": "Lucinactant", "type": "DRUG" }, { "name": "Standard Care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Windtree Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "48 Hours", "sex": "ALL", "summary": "Up to 48 Hours" }, "enrollment_count": 69, "start_date": "2000-03", "completion_date": "2004-11", "has_results": true, "last_update_posted_date": "2012-05-03", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 1, "location_summary": "Warrington, Pennsylvania", "locations": [ { "city": "Warrington", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004500" }, { "nct_id": "NCT05276492", "title": "Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma", "Prostate Neoplasm", "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Abiraterone Oral Tablet", "type": "DRUG" }, { "name": "Prednisone tablet", "type": "DRUG" }, { "name": "Drug Dairy/Log", "type": "OTHER" }, { "name": "Low-fat meal", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-01-24", "completion_date": "2024-11-16", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05276492" }, { "nct_id": "NCT04053634", "title": "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 689, "start_date": "2019-08-26", "completion_date": "2025-07-28", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 84, "location_summary": "Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more", "locations": [ { "city": "Surprise", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04053634" }, { "nct_id": "NCT02685826", "title": "A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2016-04-25", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02685826" }, { "nct_id": "NCT01742338", "title": "Dose of Corticosteroids in COPD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COPD" ], "interventions": [ { "name": "Low Dose Corticosteroids", "type": "DRUG" }, { "name": "High Dose Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 89, "start_date": "2012-05-03", "completion_date": "2020-03-15", "has_results": true, "last_update_posted_date": "2024-04-10", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • Plainsboro, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Plainsboro", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742338" }, { "nct_id": "NCT03020030", "title": "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric" ], "interventions": [ { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CYTARABINE", "type": "DRUG" }, { "name": "DASATINIB", "type": "DRUG" }, { "name": "DEXAMETHASONE", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "ETOPOSIDE", "type": "DRUG" }, { "name": "HYDROCORTISONE", "type": "DRUG" }, { "name": "LEUCOVORIN CALCIUM", "type": "DRUG" }, { "name": "MERCAPTOPURINE", "type": "DRUG" }, { "name": "METHOTREXATE", "type": "DRUG" }, { "name": "NELARABINE", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 560, "start_date": "2017-03-03", "completion_date": "2034-11", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 7, "location_summary": "Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03020030" }, { "nct_id": "NCT00573157", "title": "The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Atacicept", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 6, "start_date": "2007-12", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-03-23", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 12, "location_summary": "New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Manhasset", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573157" }, { "nct_id": "NCT00283062", "title": "Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Docetaxel (TAXOTERE®) Chemotherapy", "type": "DRUG" }, { "name": "Leuprolide acetate ( ELIGARD®) Hormonal Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 228, "start_date": "2005-12", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-01-26", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283062" }, { "nct_id": "NCT03557307", "title": "Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 598, "start_date": "2018-08-01", "completion_date": "2022-03-24", "has_results": true, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 23, "location_summary": "Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557307" }, { "nct_id": "NCT01928771", "title": "Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 2681, "start_date": "2013-09-19", "completion_date": "2016-04-05", "has_results": true, "last_update_posted_date": "2017-05-03", "last_synced_at": "2026-10-01T06:17:02.700Z", "location_count": 110, "location_summary": "Foley, Alabama • Huntsville, Alabama • Mobile, Alabama + 107 more", "locations": [ { "city": "Foley", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928771" } ] }